6. Conclusion and perspectives
Lf and its derived peptides Lfcins could be an option in the treatment of intestinal parasitic
diseases, based mainly on resultsin vitroand in animal models. Research in this glycopro-
tein has generally been leaded with success, although it is necessary to deep in the under-
standing of the mechanisms of action of Lf against parasites. In general, drugs used in the
therapy antiparasites cause toxic side effects, and/or the parasites can become resistant to
them. Lf is an innocuous protein that could be used as adjunct with drugs, with the
considerable advantage of using low doses of drugs due to the synergic effect of Lf. It
would be required more studies in animal models and carry out strict clinical trials with
methodologic accuracy and a large number of patients, in order to extend the use of Lf as a
parasiticide.
Acknowledgements
We thank to Consejo Nacional de Ciencia y Tecnologia (CONACYT) for the grants obtained to
support our research: No. CB-2012-179251 (Mireya de la Garza), No. CB-2011-167788 (Julio
César Carrero), and No. CB-2014-236546 (Nidia León-Sicairos). JCC also thanks to Programa
de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT-UNAM) for grant
No. IN206316. We also thank Dr. Luisa Samaniego and Mr. Carlos Villasana for their technical
assistance.
Abbreviations
ALA Amoebic liver abscess
apoLf Apolactoferrin
bLf Bovine Lf
BID Bowel inflammatory disease
INFγ Gamma interferon
holoLf Hololactoferrin
HIV Human immune deficiency virus
hLf Human Lf
IL Interleukin
IA Intestinal amoebiasis
IBS Irritable bowel syndrome
Lf Lactoferrin
Lfcin Lactoferricin
MEM Minimal essential medium
MIC Minimal inhibitory concentration
170 Natural Remedies in the Fight Against Parasites